According to the entity information, the object was on sale on the online platform
The National Health Surveillance Agency (Anvisa) has forbidden the sale, advertising and marketing of the smartwatch that controls diabetes and blood pressure called Glycowatch. The decision was issued on Friday 1 August.
Receive the main news directly on WhatsApp! Sign up for the Earth channel
According to the entity, the determination came after identifying the sale of smartwatches on an online platform. Anvisa reported that the product has no clinical studies that demonstrate its effectiveness and contradict the rules of decree no. 8.077/2013 of the Agency.
In February of this year, the agency issued a technical note that there are no proven glucose measurement devices.
To date, the agency has approved only five smartwatch software in Brazil, all focused on blood pressure, electrocardiogram and cardiac irregularities detection.
Source: Terra
Ben Stock is a lifestyle journalist and author at Gossipify. He writes about topics such as health, wellness, travel, food and home decor. He provides practical advice and inspiration to improve well-being, keeps readers up to date with latest lifestyle news and trends, known for his engaging writing style, in-depth analysis and unique perspectives.
